X-Account-Key: account1 X-UIDL: GmailId17894088421d39e1 X-Mozilla-Status: 0005 X-Mozilla-Status2: 00000000 X-Mozilla-Keys: Delivered-To: ac0xl.ham@gmail.com Received: by 2002:a17:90a:db13:0:0:0:0 with SMTP id g19csp1784363pjv; Fri, 2 Apr 2021 12:21:29 -0700 (PDT) X-Google-Smtp-Source: ABdhPJxVKa7mzgl7sbzje/gfa1olUuGEXHt99JUG7NlvdvxIS8bQvM5OaTiyWPp1uyv4KYue01qw X-Received: by 2002:a05:600c:2f08:: with SMTP id r8mr14072027wmn.95.1617391289415; Fri, 02 Apr 2021 12:21:29 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1617391289; cv=none; d=google.com; s=arc-20160816; b=qBXVvXtxFpQlxzE155e3SunPiISGXkf+Hy+41H+kNsGFQWY0dW68YVZf3735gYyA+F j59e8mv27rDVReHFm9jo1cCVi6+LgrAMzKzRYX+xsQsocppwyl6XvesaaYd9g0TgvfLx O2Qxs+RsuTMRqcT1r2lDAo96Theh+tbLWVolR5lZmDXFbrbY6XbKn2DvVeHq3T9gsqDN HmbK50e2lLqRCKjqNEx7ZcE56H0b/I58vFJXXiD/PaSSLEPDDYlgexgbcKWVwtN7L/eJ GHv0xTcACXjGAyb547MriZ5JaLzZWNxer4fWvqD9SdWj1W64DIgIKN14rsrhjMGMUGyr coog== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20160816; h=reply-to:precedence:message-id:mime-version:list-unsubscribe-post :list-unsubscribe:list-id:from:feedback-id:date:subject:to :dkim-signature; bh=+uEZxa6G5Q2Pg5jCEzaQYvfkBqGoRGym/qgRqeKIVbQ=; b=P9GAHC9dqFr2gfcigQTXwwoFRejjU3kEsInEYmwJqRExWXK+peV5ZjZBplIcGMF+35 lFAz1QcgRLjH/GAkbPVYjpAOk8CIROU+rqtI9ieij1WXhXgyLLkSmyooV43fO/6EJano RxWb+oVWLmR5uY/BuMfSdFJUzYds7MT+0kS9hVZYAB6UseEFKabsQNtRRM2wBS53XInR a/iJBIr73LB9hBth96h57AbssuT40JVThGGHI/DFuExifXckB2Wm6NE6mSC4AUWS43+2 98A/CAtNwqry6vopRxyJVfxMTExDSbxSYvHsYJR38X9jGnJmXLzcAXzKVoeK4Vwemcs0 5Esg== ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@sendinblue.com header.s=mail header.b=rWN0pTGB; spf=pass (google.com: domain of bounces-82kw9p41g2xjj-ac0xl.ham=gmail.com@bo.d.mailin.fr designates 185.41.28.115 as permitted sender) smtp.mailfrom="bounces-82kw9p41g2xjj-ac0xl.ham=gmail.com@bo.d.mailin.fr" Return-Path: Received: from bo.d.mailin.fr (bo.d.mailin.fr. [185.41.28.115]) by mx.google.com with ESMTPS id m14si9327512wro.529.2021.04.02.12.21.28 for (version=TLS1_3 cipher=TLS_AES_256_GCM_SHA384 bits=256/256); Fri, 02 Apr 2021 12:21:29 -0700 (PDT) Received-SPF: pass (google.com: domain of bounces-82kw9p41g2xjj-ac0xl.ham=gmail.com@bo.d.mailin.fr designates 185.41.28.115 as permitted sender) client-ip=185.41.28.115; Authentication-Results: mx.google.com; dkim=pass header.i=@sendinblue.com header.s=mail header.b=rWN0pTGB; spf=pass (google.com: domain of bounces-82kw9p41g2xjj-ac0xl.ham=gmail.com@bo.d.mailin.fr designates 185.41.28.115 as permitted sender) smtp.mailfrom="bounces-82kw9p41g2xjj-ac0xl.ham=gmail.com@bo.d.mailin.fr" DKIM-Signature: a=rsa-sha256; bh=+uEZxa6G5Q2Pg5jCEzaQYvfkBqGoRGym/qgRqeKIVbQ=; c=relaxed/relaxed; d=sendinblue.com; h=to:cc:from:reply-to:subject:date:mime-version:content-type:list-id:list-unsubscribe:x-csa-complaints:list-unsubscribe-post:message-id:sender:x-sib-id:x-mailin-client:x-mailin-campaign:feedback-id; q=dns/txt; s=mail; t=1617391208; v=1; b=rWN0pTGBD4IltnbHpBJOlcd61m5ToEyLz9DhmRzUE9GfnFT5z93Td3U5eL2MWnuNNHPfqyKY JoeO8EqkUq6YksQKrWoec7EsXNRyFkRWNwV9p3idWOzeganQOhfbkHizRMnIKeZR4nxCVUmQ5zf XqhxGVM77si7bjKGRrtQ9WeM= To: Subject: =?utf-8?q?Andreas_Kalcker_|_=E2=9C=85_ESTUDIO_CL=C3=8DNICO_con_DI=C3=93XI?= =?utf-8?q?DO_DE_CLORO_totalmente_EFECTIVO_contra_la_COVID-19?= Content-Type: multipart/alternative; boundary="-------?=_15640-1983947542735" Date: Fri, 02 Apr 2021 19:20:08 +0000 Feedback-ID: 185.41.28.115:1853671_152:1853671:Sendinblue From: Andreas L. Kalcker List-Id: MTg1MzY3MS01MDUzOS00OA== List-Unsubscribe: , List-Unsubscribe-Post: List-Unsubscribe=One-Click MIME-Version: 1.0 Message-Id: <202102041920.82kw9p41g2xjj@bo.d.mailin.fr> Precedence: bulk Reply-To: info@andreaskalcker.com X-Csa-Complaints: whitelist-complaints@eco.de X-Mailer: Sendinblue X-Mailin-Campaign: 152 X-Mailin-Client: 1853671 X-sib-id: 8RaGH2_tR2VuiZFX78WEG_leMicFXLErmd6fKy4s1J2ULCRW-KBHZncTHUsAbrtbAmu7IuxupaFghNrLJXJo0rDOKGeYg8-xBqoGmOReSHFOCoU41d17eWU9WdL51T-f62GFOR_CG9SDeuduOGvlOScvupuglHkD_vP4r4A ---------?=_15640-1983947542735 Content-Transfer-Encoding: quoted-printable Content-Type: text/plain; charset=UTF-8 [ ]( # ) [ ]( # ) =C2=A0 =C2=A0 [ ]( # ) [ ]( https://310qd.r.ag.d.sendibm3.com/mk/cl/f/VRznVmeImCThAtuDN-MV3mqHSDC= kNT0ZQbqMsWKWLnN2TYvGVgRJdieRKIEHIkLDwTPgtzh5saL7EAmhyFlkQES1_hkKSIpdcw0Tdj= 7XwTx-l5i-sN04PXdE1McowObrMcf_NXiTfIAvS7LQJ3HJ6yUf6nl1xHcKoZXp0VV5AO88teosv= KylJwTCeQYY-dKrmmSsjGuz6v-U82sequ48IhLnVYLxkM5dbyrvFbgWPUNAa3jchxN0EnjU6g ) [ ]( # ) =C2=A0 Ya tiene la oportunidad de leer el primer estudio cl=C3=ADnico multic=C3=A9= ntrico llevado a cabo en varios pa=C3=ADses de Am=C3=A9rica latina que demu= estra claramente que el di=C3=B3xido de cloro es un tratamiento totalmente = efectivo contra la COVID-19. =C2=A0 Se trata nada m=C3=A1s y nada menos que del primer estudio cient=C3=ADfico = en seres humanos con di=C3=B3xido de cloro para uso terap=C3=A9utico. =C2=A0 Este estudio excepcional ha sido registrado y aceptado en clinicaltrials.go= v el 7 de abril de 2020 (NCT 04343742) y entra dentro de los estudios categ= orizados como ECE (estudios piloto cuasiexperimentales) por el NCBI (Nation= al Center for Biotechnology Information) . =C2=A0 Si desea acceder a este estudio pionero y ampliar su conocimiento al respec= to puede hacerlo desde el siguien enlace. =C2=A0 =C2=A0 [ ]( # ) =C2=A0 [ VER ESTUDIO CL=C3=8DNICO ]( https://310qd.r.ag.d.se= ndibm3.com/mk/cl/f/m_df4FEBN91CocoFRSBb1rfWDoTOZcnFYbfRhSKCaUMd4_mrZ5xCTqhy= rMX2H9W_SPFgcRu6HJ64VDedJmKtHAhYQK8LiF8YFDxH8KcOTDHeCB4APkz-HjAHZ2ztySR3f1o= kOt3uHyDsRpsLnRWj0WOrsBcIIH8pauTbS-cLvdNKttATPtW958zEQjIN6KyEK6dXRC3lyJjtMA= k2QTDbtC-OpOHwlTbW0NsmlNTA8GjXd-grDpog-2JbIg ) =C2=A0 [ ]( # ) [ ]( # ) [ ]( https://310qd.r.ag.d.sendibm3.com/mk/cl/f/9JV2PMSaHnWz8XhiwRdGZNiVDQh= qtiISf8Yep95DnZkpaU93T-iWOewONX2XwbIfyfctD9I6F-XYHOy5LGpI-JmGqI2I3alJJlFkAs= GbTSA7uzdB_yFvY-s89M0S-_Fm0zV_hcZQ0yIRszUDdC8wis0qYIcPJQjf2pcXIlEAztfQUhKmm= ixtoN8LmLBHPEAVjNQsQGNC4Pxlzx2YZHZIPlFL_YeL-231xB4JyQtrcTFRUfntzwRh0yuD3LGL= 97jG ) [ ]( # ) =C2=A0 You can now read the first multi-center clinical study conducted in several= Latin American countries demonstrating very clearly that Chlorine Dioxide = is a fully effective treatment for COVID-19. =C2=A0 This is the very first Chlorine Dioxide scientific study carried out on hum= an beings for therapeutical purposes. =C2=A0 This exceptional study has been registered and accepted in clinicaltrials.g= ov on April 7, 2020 (NCT 04343742) and falls within the studies categorized= as ECE (quasi-experimental pilot studies) by the NCBI (National Center for= Biotechnology Information). =C2=A0 If you want to access this pioneering study and learn more about it you can= do it here. =C2=A0 [ ]( # ) =C2=A0 [ LEARN MORE ]( https://310qd.r.ag.d.sendibm3.com/mk/= cl/f/WQJsR1QEXwSVs3cpWYt-WdScTWDHMij1fx12Zy449OL7RTpnbj2VUIJuNweBJ1o8yz28cv= SxE5F6K4fstFTpkgvCIMU8R9qcwnxF8EmEneiPRNZr0UyPk75FxmbpembmqZa056T_E13s1A8tF= Z2tRBZQImA1v3kUUUtALFtx105yZNldZwMH7r2ji2rWM-1sqxh9vj3EjK9m1_78ulz2zRss2KPc= YaMJT3XIe8vbBJaIavPPL_0Dq9CQt5LUqDkr ) =C2=A0 [ ]( # ) =C2=A0 Se ha enviado este e-mail a ac0xl.ham@gmail.com Ha recibido este e-mail porque est=C3=A1 suscrito a andreaskalcker.com =C2=A0 [ Cancelar la suscripci=C3=B3n ]( https://310qd.r.ag.d.sendibm3.com/mk/un/f= YuEH-_ESI_dvyiAHMiSwYr1MVyxKya27Qi2nI1Wx9QXZBQVYU-KE0eRYPHbfMx5avIjIeVE4h75= 2vR-rjX5OXWepNgozGulL_hLZciUyyqRztrarq4k0b3INh2ReKRO4PDEJIkbjSu2TQms7Q ) = =C2=A0 ---------?=_15640-1983947542735 Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset=UTF-8 =20
3D""
=20 =20
=C2=A0
=20
3D"andreaskalcker.com"
=C2=A0
=20 =20
=20 =20
3D""
=20 =20
=20 =20
=C2=A0
Ya tiene la oportunidad= de leer el primer estudio cl=C3=ADnico multic=C3=A9ntrico= llevado a cabo en varios pa=C3=ADses de Am=C3=A9rica latina que demuestra claramente que el di=C3=B3xido de cloro es un trat= amiento totalmente efectivo contra la COVID-19.
=C2=A0
Se trata nada m=C3=A1s y nada menos qu= e del primer estudio cient=C3=ADfico en seres humanos con di=C3=B3x= ido de cloro para uso terap=C3=A9utico.
=C2=A0
Este estudio excepcional ha sido registrado y aceptado en clinicaltrials.gov el 7 de abril de 20= 20 (NCT 04343742) y entra dentro de los estudios categorizados como ECE (es= tudios piloto cuasiexperimentales) por el NCBI (National Center for Biotech= nology Information) .
=C2=A0
Si desea acceder a este estudio pioner= o y ampliar su conocimiento al respecto puede hacerlo desde el siguien enla= ce.
=C2=A0
=C2=A0
=20
=20 =20
=C2=A0
= VER ESTUDIO CL=C3=8DNICO =
=C2=A0
=20 =20
3D""
=20 =20
3D"SALUD
=20 =20
=20 =20
=C2=A0
You can now read the first multi-center clinical study conducted in several Latin American countries demonstrating very clearly that Chlorine Dioxide is a fully effective treatment for COVID-19.
=C2=A0
This is the very first Chlorin= e Dioxide scientific study carried out on human beings for therapeutical pu= rposes.
=C2=A0
This exceptional study has been registered and accepted in clinicaltrials.gov on April 7, 2020 (= NCT 04343742) and falls within the studies categorized as ECE (quasi-experi= mental pilot studies) by the NCBI (National Center for Biotechnology Inform= ation).
=C2=A0
If you want to access this pioneering = study and learn more about it you can do it here.
=C2=A0
=20
=20 =20
=C2=A0
= LEARN MORE =
=C2=A0
=20 =20
=20
=C2=A0
Se ha enviado este e-mail a ac0xl.ham@gmail.com
Ha recib= ido este e-mail porque est=C3=A1 suscrito a andreaskalcker.com
= =C2=A0
=C2=A0
=20
---------?=_15640-1983947542735--